Amicus Therapeut Stock Price, News & Analysis

Dimerix and Amicus Therapeutics have formed an exclusive license agreement for DMX-200 in the United States. The deal focuses on treating Focal Segmental Glomerulosclerosis (FSGS), a rare and fatal kidney disease with no FDA-approved therapies.

Key financial terms include:

• US$30 million upfront payment to Dimerix
• Up to US$560 million in success-based milestone payments
• Tiered royalties on U.S. sales from low-teens to low-twenties percentages

DMX-200 is currently in a pivotal Phase 3 trial called ACTION3, with positive interim results showing better performance than placebo in reducing proteinuria. The FDA has aligned on proteinuria as the primary endpoint for marketing approval. Full trial enrollment is expected by year-end 2025. Amicus will handle U.S. regulatory submissions and commercialization, while Dimerix retains rights in other territories.

Amicus Therapeutics (FOLD) has scheduled its first quarter 2025 financial results conference call and audio webcast for Thursday, May 1, 2025, at 8:30 a.m. ET. The event will cover financial performance for Q1 ending March 31, 2025.

Participants must pre-register online to receive dial-in details and a personal PIN for phone access. A live webcast and presentation materials will be available through the Investors section at ir.amicusrx.com, with recommended registration 15 minutes before the call. An archived version and slides will be accessible post-event on the company website.

Amicus Therapeutics (Nasdaq: FOLD), a patient-focused biotechnology company specializing in rare diseases, has announced its participation in two major investor conferences in March 2025:

• TD Cowen 45th Annual Health Care Conference in Boston, MA on March 4, 2025, at 9:50 a.m. ET
• Leerink Partners 2025 Global Healthcare Conference in Miami, FL on March 10, 2025, at 10:00 a.m. ET

Both presentations will be accessible via live audio webcast through the investors section of the Amicus Therapeutics corporate website. The company focuses on discovering, developing, and delivering innovative first- or best-in-class medicines for rare disease patients.

Amicus Therapeutics (FOLD) reported strong financial results for 2024, with total revenue reaching $528.3 million, marking a 33% year-over-year increase. The company's two main products showed significant growth: Galafold generated $458.1 million (+18% YoY) and Pombiliti + Opfolda contributed $70.2 million.

For 2025, Amicus projects total revenue growth of 17-24%, with Galafold expected to grow 10-15% and Pombiliti + Opfolda forecasted to increase 65-85%. The company anticipates achieving positive GAAP net income during H2 2025 and expects to surpass $1 billion in total sales by 2028.

The company's GAAP net loss for 2024 was $56.1 million ($0.18 per share), significantly improved from a $151.6 million loss in 2023. Cash position remained stable at $249.9 million as of December 31, 2024.

Amicus Therapeutics (FOLD) has scheduled a conference call and live audio webcast for February 19, 2025, at 8:30 a.m. ET to discuss their full-year 2024 financial results. Participants must pre-register online to receive dial-in details and a personal PIN for phone access. A webcast will be available through the Investors section of Amicus' website, with participants advised to register 15 minutes before the call starts.

The presentation materials and archived webcast will be accessible on the company's website after the event. Amicus Therapeutics is a global biotechnology company focused on developing and delivering medicines for rare diseases.

Amicus Therapeutics (FOLD) announced its participation at the 21st Annual WORLDSymposium™ 2025, featuring two oral presentations and 20 posters focused on Fabry and Pompe diseases. The presentations include key findings on miglustat, a first-in-class enzyme stabilizer for late-onset Pompe disease, and improvements in patients switching to cipaglucosidase alfa plus miglustat treatment.

The extensive poster sessions cover various aspects of both diseases, including patient experiences, treatment outcomes, and clinical studies. Notable presentations include long-term safety data of migalastat in Fabry disease patients, real-world evidence studies, and results from the PROPEL study showing clinical improvements in Pompe disease patients.

Amicus Therapeutics (FOLD) reported preliminary 2024 total revenue of $528.5M, showing significant growth of 32% year-over-year. The company's performance was driven by two key products: Galafold, with net sales of $458.2M (18% growth), serving ~2,730 Fabry disease patients, and Pombiliti + Opfolda, with net sales of $70.3M, treating ~220 patients in its first full launch year.

For 2025, Amicus projects total revenue growth of 17-24% at constant exchange rates, with Galafold expected to grow 10-15% and Pombiliti + Opfolda 65-85%. The company secured multiple pricing and reimbursement agreements in late 2024/early 2025, including Italy, Sweden, Switzerland, and Czech Republic. A settlement with Teva ensures no generic migalastat in the U.S. until 2037. Amicus anticipates reaching positive GAAP Net Income in H2 2025 and surpassing $1 billion in total sales by 2028.

Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bradley Campbell, President and Chief Executive Officer, will deliver a presentation in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT.

The presentation will be accessible through a live audio webcast via the investors section of the Amicus Therapeutics corporate website. The company, dedicated to discovering, developing, and delivering novel medicines for rare diseases, maintains a commitment to advancing its pipeline of first- or best-in-class medicines.